Tempus Validates PurIST for Pancreatic Cancer Treatment
September 9, 2025
Real-world evidence demonstrates PurIST’s ability to guide first-line treatment decisions and improve outcomes for patients with advanced pancreatic ductal adenocarcinoma Tempus AI, a technology company